Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience.
Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience.
复制标题
DOI：
10.3389/fimmu.2022.832419
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
Meng X
中科院分区：
文献类型：
--
作者：
Bai M;Wang W;Gao X;Wu L;Jin P;Wu H;Yu J;Meng X
免疫检查点抑制剂（ICI）在EGFR突变NSCLC患者中的作用存在争议。在这项研究中，我们的目的是研究ICI单独或联合治疗EGFR突变NSCLC患者的晚期治疗效果，并探索可能预测ICI疗效的因素。我们回顾性收集了75例确诊EGFR突变患者的临床和病理信息。所有患者均对EGFR-TKI产生了获得性耐药，并于2019年1月至2021年1月在山东省癌症医院和研究所接受了ICIs治疗。通过肿瘤反应和生存率评价治疗效果。中位随访时间为7.3个月（范围1.8-31.8个月）。总有效率（ORR）为8.0%，疾病控制率（DCR）为78.7%。所有患者的中位PFS为3.9个月（95% CI，2.7-5.0），而中位OS为9.9个月（95% CI，5.3-14.6）。我们发现EGFR-TKI反应持续时间较长的患者（≥10个月）显示，与PFS-TKI较短的患者相比，接受免疫治疗的患者PFS较长中位PFS分别为5.2个月[95%CI 4.2-6.2]和2.8个月[2.0-3.6（HR，0.53，95%CI，0.31-0.91，P=0.005）。在探索性分析中，我们发现同时进行颅外放疗和较高的体重指数（BMI）与较长的PFS相关（P值分别为0.006和0.021）。我们发现免疫治疗加化疗加抗血管生成药物的联合方案可能会延长EGFR突变NSCLC患者的生存期。我们还发现，PFS-TKI时间较长、同时进行颅外放疗和BMI较高的患者可能从免疫治疗中获益更多。
The role of immune checkpoint inhibitors (ICIs) in NSCLC patients with EGFR mutations are controversial. In this study, we aim to investigate the therapeutic efficacy of ICIs alone or in combination in patients with EGFR mutated NSCLC in late-line settings, and explore the factors that may predict the efficacy of ICIs. We retrospectively collected the clinical and pathological information of 75 patients with confirmed EGFR mutations. All patients have developed acquired resistance to EGFR-TKIs, and were treated with ICIs in late line settings from January 2019 to January 2021, at Shandong Caner Hospital and Institute. Therapeutic efficacy was evaluated by tumor response and survival. The median follow-up period was 7.3months (range 1.8-31.8 months). The overall response rate (ORR) was 8.0%, and the disease control rate (DCR) was 78.7%. The median PFS for all patients was 3.9 months (95% CI, 2.7-5.0), while the median OS was 9.9 months (95% CI, 5.3-14.6). We found that patients with longer response duration to EGFR-TKIs (≥10 months) showed a longer PFS when treated with immunotherapy compared with patients with shorter PFS-TKI (<10 months), the median PFS in two groups were 5.2 months [95%CI 4.2-6.2] and 2.8 months [2.0-3.6]) respectively (HR, 0.53, 95%CI, 0.31-0.91, P=0.005). In exploratory analysis, we found that concurrent extracranial radiotherapy and higher body mass index (BMI) are associated with longer PFS (P values are 0.006 and 0.021 respectively). We found that combination regimen of immunotherapy plus chemotherapy plus antiangiogenetic agents may yield longer survival in patients with EGFR mutated NSCLC. We also found that patients with longer PFS-TKI, concurrent extracranial radiotherapy and higher BMI may benefit more from immunotherapy.
登录
查看更多内容
DOI：
10.1016/j.jtho.2018.03.035
发表时间：
2018-08
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者：
Garon EB
影响因子：
76.2
作者：
Reck, Martin;Mok, Tony S. K.;Socinski, Mark A.
通讯作者：
Socinski, Mark A.
影响因子：
8.8
作者：
Gahr, S.;Stoehr, R.;Geissinger, E.;Ficker, J. H.;Brueckl, W. M.;Gschwendtner, A.;Gattenloehner, S.;Fuchs, F. S.;Schulz, C.;Rieker, R. J.;Hartmann, A.;Ruemmele, P.;Dietmaier, W.
通讯作者：
Dietmaier, W.
影响因子：
4.7
作者：
Liu S;Wu F;Li X;Zhao C;Jia Y;Jia K;Han R;Qiao M;Li W;Yu J;Zhou F;Xiong A;Chen B;Fan J;Ren S;Zhou C
通讯作者：
Zhou C
DOI：
10.4049/jimmunol.1701738
发表时间：
2018-10-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Murphy KA;James BR;Sjaastad FV;Kucaba TA;Kim H;Brincks EL;Chua SC Jr;Wilber A;Griffith TS
通讯作者：
Griffith TS